Vasculitis Anki Flashcards
Card 1: Classification by Vessel Size
Front: What are the three main categories of vasculitis based on vessel size?
Back:
- Large vessel vasculitis: Giant cell arteritis (GCA), Takayasu arteritis (TAK)
- Medium vessel vasculitis: Polyarteritis nodosa, Kawasaki disease
- Small vessel vasculitis: ANCA-associated vasculitis (GPA, MPA, EGPA), IgA vasculitis (Henoch-Schönlein purpura), cryoglobulinemic vasculitis 1
Card 2: ANCA-Associated Vasculitis - Definition
Front: What are the three types of ANCA-associated vasculitis (AAV)?
Back:
- Granulomatosis with polyangiitis (GPA) - formerly Wegener's
- Microscopic polyangiitis (MPA)
- Eosinophilic granulomatosis with polyangiitis (EGPA) - formerly Churg-Strauss 2, 3
Card 3: AAV Pathophysiology
Front: What is the pathophysiology of ANCA-associated vasculitis?
Back:
- Autoantibodies: PR3-ANCA or MPO-ANCA target neutrophil antigens
- Mechanism: Antibodies activate primed neutrophils causing degranulation and release of toxic oxygen radicals
- Result: Necrotizing inflammation of small vessels (capillaries, venules, arterioles)
- Tissue damage: Leads to glomerulonephritis, pulmonary hemorrhage, and systemic inflammation 2, 4
Card 4: AAV Organ-Threatening Manifestations
Front: What are examples of organ/life-threatening manifestations in AAV?
Back:
- Glomerulonephritis
- Pulmonary hemorrhage
- Meningeal/CNS involvement
- Retro-orbital disease
- Cardiac involvement
- Mesenteric involvement
- Mononeuritis multiplex 2
Card 5: AAV Non-Organ-Threatening Manifestations
Front: What are examples of non-organ-threatening manifestations in AAV?
Back:
- Nasal/paranasal disease without bony erosion
- Skin involvement without ulceration
- Skeletal myositis
- Non-cavitating pulmonary nodules
- Episcleritis 2
Card 6: AAV Diagnosis - ANCA Testing
Front: What is the recommended approach to ANCA testing in suspected AAV?
Back: Test for BOTH PR3-ANCA and MPO-ANCA using high-quality antigen-specific assays as the primary method (not immunofluorescence alone)
- PR3-ANCA (cANCA): Highly specific for GPA, predicts prognosis
- MPO-ANCA (pANCA): Associated with MPA, less specific
- Biopsy strongly recommended to confirm diagnosis 2, 4
Card 7: AAV Treatment - Organ-Threatening Disease
Front: What is the recommended induction treatment for organ/life-threatening AAV?
Back: Glucocorticoids PLUS rituximab OR cyclophosphamide
- Rituximab is preferred for relapsing disease
- Glucocorticoid dosing: 50-75 mg prednisolone/day initially
- Taper: Reduce to 5 mg/day by 4-5 months
- Avacopan may be added to substantially reduce glucocorticoid exposure 2, 3
Card 8: AAV Treatment - Non-Organ-Threatening Disease
Front: What is the recommended treatment for non-organ-threatening AAV?
Back: Glucocorticoids plus rituximab
- Alternatives to rituximab: Methotrexate or mycophenolate mofetil
- Same glucocorticoid dosing and taper as organ-threatening disease 2
Card 9: AAV - Plasma Exchange Indication
Front: When should plasma exchange be considered in AAV?
Back: Consider for serum creatinine >300 µmol/L due to active glomerulonephritis
- NOT routinely recommended for alveolar hemorrhage
- Used in combination with standard immunosuppression 2
Card 10: AAV Complications
Front: What are major complications of AAV and its treatment?
Back: Disease complications:
- End-stage renal disease
- Permanent vision loss
- Respiratory failure
- Stroke/neurologic deficits
Treatment complications:
- Infections (from immunosuppression)
- Osteoporosis (from glucocorticoids)
- Malignancy risk
- Cumulative organ damage from drug toxicity 5, 6
Card 11: Giant Cell Arteritis - Key Symptoms
Front: What are the key symptoms of giant cell arteritis (GCA)?
Back:
- New-onset persistent localized headache (often temporal)
- Jaw/tongue claudication
- Acute visual symptoms: Amaurosis fugax, diplopia, acute vision loss
- Constitutional symptoms: Weight loss >2 kg, fever, fatigue
- Polymyalgia rheumatica symptoms
- Limb claudication 7
Card 12: GCA - Physical Examination Findings
Front: What are key physical examination findings in giant cell arteritis?
Back:
- Temporal artery tenderness/thickening with reduced pulsation
- Scalp tenderness
- Bruits (particularly axillary)
- Reduced pulses/blood pressure in upper limbs
- Ophthalmologic findings: Anterior ischemic optic neuropathy, cranial nerve palsies, retinal artery occlusion 7
Card 13: GCA Pathophysiology
Front: What is the pathophysiology of giant cell arteritis?
Back:
- Granulomatous inflammation of large and medium arteries
- Primarily affects: Aorta and its major branches, especially extracranial carotid arteries
- Histology: Multinucleated giant cells, fragmentation of internal elastic lamina
- Result: Vessel wall thickening, luminal narrowing, ischemia of supplied territories 7, 1
Card 14: GCA Treatment
Front: What is the treatment for giant cell arteritis?
Back: Immediate high-dose glucocorticoids: 40-60 mg/day prednisolone
- Start BEFORE diagnostic confirmation if visual symptoms present (strongest risk factor for blindness is treatment delay)
- Taper: To 15-20 mg/day within 2-3 months, then ≤5 mg/day by 1 year
- Fast-track referral: Within 24 hours to specialized center for imaging/biopsy 7
Card 15: GCA Complications
Front: What are the major complications of giant cell arteritis?
Back:
- Permanent blindness (most feared, preventable with early treatment)
- Stroke
- Aortic aneurysm/dissection
- Limb ischemia
- Treatment-related: Glucocorticoid toxicity (osteoporosis, diabetes, infections) 7, 6
Card 16: Takayasu Arteritis - Key Symptoms
Front: What are the key symptoms of Takayasu arteritis?
Back:
- New/worsening limb claudication
- Constitutional symptoms: Weight loss >2 kg, fever, fatigue, night sweats
- Myalgia, arthralgia, arthritis
- Severe abdominal pain
- Stroke, seizures (non-hypertensive), syncope, dizziness
- Myocardial infarction, angina
- Acute visual symptoms 7
Card 17: Takayasu Arteritis - Physical Findings
Front: What are key physical examination findings in Takayasu arteritis?
Back:
- Hypertension (>140/90 mmHg)
- Loss of pulses, pulse inequality
- Bruits (over affected vessels)
- Carotidynia (carotid artery tenderness)
- Blood pressure discrepancies between limbs 7
Card 18: Takayasu Arteritis Pathophysiology
Front: What is the pathophysiology of Takayasu arteritis?
Back:
- Granulomatous inflammation of large vessels
- Primarily affects: Aorta and its major branches
- Mechanism: T-cell mediated inflammation, giant cell infiltration
- Result: Vessel wall thickening, stenosis, aneurysm formation, thrombosis
- Demographics: Predominantly affects young women (<40 years) 7, 1
Card 19: Takayasu Arteritis Treatment
Front: What is the treatment for Takayasu arteritis?
Back: High-dose glucocorticoids: 40-60 mg/day prednisolone
- Taper: To 15-20 mg/day within 2-3 months, then ≤10 mg/day by 1 year
- Multidisciplinary management: Requires specialist team with imaging expertise
- Additional immunosuppression often needed for refractory disease 7
Card 20: Takayasu Arteritis Complications
Front: What are major complications of Takayasu arteritis?
Back:
- Aortic regurgitation
- Aortic aneurysm/dissection
- Renovascular hypertension
- Stroke
- Myocardial infarction
- Limb ischemia requiring revascularization
- Pulmonary hypertension 7, 6
Card 21: Polyarteritis Nodosa - Features
Front: What are the key features of polyarteritis nodosa (PAN)?
Back: Medium vessel necrotizing vasculitis WITHOUT glomerulonephritis or pulmonary involvement
- Symptoms: Fever, weight loss, myalgia, peripheral neuropathy (mononeuritis multiplex), abdominal pain, testicular pain
- Skin: Livedo reticularis, nodules, ulcers
- Associated: Hepatitis B in some cases
- ANCA-negative 1, 8
Card 22: Polyarteritis Nodosa Treatment
Front: What is the treatment for polyarteritis nodosa?
Back: Glucocorticoids improve prognosis
- Systemic PAN: Glucocorticoids + cyclophosphamide for severe disease
- Cutaneous PAN: Colchicine or dapsone
- Hepatitis B-associated: Antiviral therapy + short-course steroids, consider plasma exchange 8
Card 23: IgA Vasculitis (Henoch-Schönlein Purpura)
Front: What are the key features of IgA vasculitis (Henoch-Schönlein purpura)?
Back: Small vessel vasculitis with IgA immune complex deposition
- Classic tetrad: Palpable purpura (lower extremities/buttocks), arthralgia, abdominal pain, glomerulonephritis
- Pathophysiology: IgA-containing immune complexes deposit in vessel walls
- More common in children
- Diagnosis: Skin/renal biopsy shows IgA deposition 8, 4
Card 24: IgA Vasculitis Treatment
Front: What is the treatment for IgA vasculitis (Henoch-Schönlein purpura)?
Back: Most cases self-limited, symptomatic treatment sufficient
- Mild disease: NSAIDs for arthralgia, supportive care
- Severe glomerulonephritis in adults: Insufficient evidence for glucocorticoids, use ACE inhibitors based on symptoms
- Hemorrhagic skin lesions suggesting necrosis: Consider glucocorticoids 8
Card 25: Leukocytoclastic Vasculitis
Front: What are the features and treatment of leukocytoclastic vasculitis?
Back: Small vessel vasculitis with neutrophil infiltration and nuclear debris
- Causes: Drugs, infections, connective tissue diseases, malignancy
- Presentation: Palpable purpura, typically lower extremities
- Pathology: IgG or IgM immune complexes (better prognosis than IgA)
- Treatment: Remove trigger if identified; for chronic/relapsing disease use colchicine or dapsone; glucocorticoids if skin necrosis threatens 8, 4
Card 26: Cryoglobulinemic Vasculitis
Front: What are the features and treatment of cryoglobulinemic vasculitis?
Back: Small vessel vasculitis from cryoglobulin immune complex deposition
- Triad: Palpable purpura, arthralgia, weakness
- Associated: Hepatitis C (most common), lymphoproliferative disorders
- Lab: Low C4, positive cryoglobulins, positive rheumatoid factor
- Treatment: Treat underlying disease (antivirals for HCV, treat lymphoma/myeloma); plasma exchange for severe cases 8, 4
Card 27: Urticarial Vasculitis
Front: What distinguishes urticarial vasculitis from ordinary urticaria?
Back: Urticarial lesions that last >24 hours and leave residual hyperpigmentation
- Pathophysiology: Small vessel vasculitis with immune complex deposition
- Symptoms: Painful/burning urticarial lesions (vs. pruritic in ordinary urticaria)
- May have: Arthralgia, low complement (hypocomplementemic urticarial vasculitis syndrome)
- Treatment: Dapsone or colchicine usually first-line 8
Card 28: AAV Prophylaxis and Monitoring
Front: What prophylaxis and monitoring is recommended for patients with AAV on treatment?
Back: Mandatory prophylaxis:
- PCP prophylaxis (trimethoprim-sulfamethoxazole) during intensive immunosuppression
- Osteoporosis prevention: Calcium, vitamin D, bisphosphonates
- Lifestyle advice: Smoking cessation, infection prevention
Periodic screening for:
- Treatment-related infections
- Malignancy
- Cardiovascular disease
- Bone health 2
Card 29: AAV Multidisciplinary Management
Front: Why is multidisciplinary management essential in AAV?
Back: AAV is rare, heterogeneous, and potentially life/organ-threatening
Requires expertise in:
- Rheumatology (primary management)
- Nephrology (renal involvement)
- Pulmonology (lung involvement)
- ENT (upper airway disease)
- Ophthalmology (ocular complications)
- Neurology (peripheral/CNS involvement)
Patients should be managed at or have access to specialized vasculitis centers 2, 3
Card 30: Vasculitis - General Diagnostic Approach
Front: What is the essential diagnostic approach for suspected vasculitis?
Back: Biopsy is nearly always essential for diagnosis (except Takayasu arteritis where aortography is indicated)
Key steps:
- Detailed history: Onset, course, organ systems affected
- Physical examination: Assess extent of involvement
- Laboratory tests: ANCA, inflammatory markers (ESR/CRP), complement, cryoglobulins
- Imaging: Based on suspected vessel size (ultrasound, CT angiography, MR angiography, PET-CT)
- Tissue biopsy: From involved organ when feasible 1, 6